e-learning
resources
Madrid 2019
Wednesday, 02.10.2019
Tuberculosis: treatment and management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Statin with standard antituberculosis regimen and mortality in hospitalized pulmonary tuberculosis
T. Jeeraaumponwat (Khon Kaen, Thailand)
Source:
International Congress 2019 – Tuberculosis: treatment and management
Session:
Tuberculosis: treatment and management
Session type:
Poster Discussion
Number:
5280
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Jeeraaumponwat (Khon Kaen, Thailand). Statin with standard antituberculosis regimen and mortality in hospitalized pulmonary tuberculosis. 5280
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Side-effect in the treatment of pulmonary tuberculosis by first-line drugs
Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities
Year: 2009
Efficacy of a standard chemotherapy regimen in the management of sputum-positive pulmonary TB relapses
Source: Eur Respir J 2003; 22: Suppl. 45, 41s
Year: 2003
Corticosteroids as adjunctive therapy in tuberculosis pneumonia with ART
Source: Breathe 2008; 5: 274
Year: 2009
Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 339s
Year: 2001
Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis?
Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis
Year: 2008
Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011
Clinical efficacy of new anti-TB drug ²tubelon² during complex chemotherapy in patients with first-time diagnosed destuctive pulmonary TB
Source: Eur Respir J 2006; 28: Suppl. 50, 8s
Year: 2006
Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen
Source: Eur Respir J 2002; 20: Suppl. 38, 359s
Year: 2002
Relapse and failure pulmonary tuberculosis patients have the chance of cure with major antituberculosis drugs
Source: Eur Respir J 2007; 30: Suppl. 51, 657s
Year: 2007
The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Efficacy of standard chemotherapy regimen in patients with newly detected sputum-positive destructive pulmonary tuberculosis
Source: Eur Respir J 2003; 22: Suppl. 45, 40s
Year: 2003
Treatment results of new cases of sputum-positive pulmonary tuberculosis with standard chemotherapeutical regimen
Source: Eur Respir J 2002; 20: Suppl. 38, 367s
Year: 2002
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019
Tolerance to chemotherapy regimens with bedaquiline in adolescents with MDR/XDR pulmonary TB
Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis
Year: 2021
Sudden deaths amongst inpatients with active pulmonary tuberculosis following commencement of antimicrobial therapy
Source: Eur Respir J 2003; 22: Suppl. 45, 158s
Year: 2003
Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid
Source: Eur Respir J 2015; 45: 1498-1501
Year: 2015
Response to empirical anti-tuberculosis treatment in patients with sputum smear-negative pulmonary tuberculosis
Source: Eur Respir J 2006; 28: Suppl. 50, 845s
Year: 2006
Efficiency of intravenous treatment with levofloxacin in patients with MDR pulmonary tuberculosis in the intensive phase of chemotherapy
Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis
Year: 2021
Standardized second-line anti-TB treatment of multidrug-resistant tuberculosis during pregnancy; maternal and neonatal safety and outcome
Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept